Immunology Clinical Trials Update: Week 26, 2026

Published June 26, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Mycophenolate Mofetil with Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy

This phase 2 trial from Fox Chase Cancer Center is exploring a new treatment approach for immune-related hepatitis caused by cancer immunotherapy. Combining mycophenolate mofetil with prednisone aims to reduce liver inflammation while potentially lowering the side effects commonly seen with steroids. The study plans to enroll 31 patients who have developed moderate to severe hepatitis after checkpoint inhibitor therapy, offering hope for better management of this challenging complication.

Identification of B Regulatory Cells by Flow Cytometry

Researchers at Hull University Teaching Hospitals NHS Trust are investigating a blood test that measures B-regulatory cells in patients with pollen and venom allergies. By tracking these cells during allergen immunotherapy, the study hopes to find markers that show whether treatment is working and if allergy tolerance is improving. This could lead to better ways to monitor allergy treatments and personalize care for patients in the United Kingdom.

Protocol of Reintroduction of Beta-lactams in Children at Low Risk of Anaphylaxis

This French study completed enrollment with 195 children under 16 years old who have a low risk of allergic reactions to beta-lactam antibiotics. It tests a simpler oral reintroduction method without prior skin testing to confirm drug allergies. Results could help reduce unnecessary avoidance of these common antibiotics, making treatment safer and easier for children suspected of having drug allergies.

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

The National Institute of Allergy and Infectious Diseases is conducting a phase 2 trial to see if the drug ruxolitinib can help patients with APECED-related alopecia areata regain hair. This rare autoimmune condition causes severe hair loss, and new treatment options are limited. The study is open to patients aged 12 to 65 in the United States and could lead to a valuable therapy for this difficult-to-treat form of hair loss.

Clonal Fetal Mesenchymal Stem Cells (cfMSCs) for the Control of Immune-related Disorders

A phase 1 trial in China is testing a novel cell therapy using clonal fetal mesenchymal stem cells to treat patients with immune-related disorders and tissue damage. This approach aims to control severe symptoms by regulating the immune system in new ways. The study plans to enroll 100 participants and could pave the way for innovative treatments for complex immune conditions.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.